Article Sidebar

PDF (Tiếng Việt)
Published: 2023-11-30
Abstract Views: 141
Views PDF (Tiếng Việt): 123
DOI: https://doi.org/10.52852/tcncyh.v172i11.1942
Issue
Vol. 172 No. 11 (2023)
Section
Các bài báo
How to Cite
Thơ, P. K. A., Minh, L. V., Đệ, T. V., Phương, P. V., Bình, N. T., Tùng, L. Đình, & Khải, T. Q. (2023). 2. Genotypes on HLA-DRB1 locus and association with myasthenia gravis. Journal of Medical Research, 172(11), 11-22. https://doi.org/10.52852/tcncyh.v172i11.1942

2. Genotypes on HLA-DRB1 locus and association with myasthenia gravis

Pham Kieu Anh Tho, Le Van Minh, Tran Van De, Pham Van Phuong, Nguyen Thanh Binh, Le Dinh Tung, Tran Quang Khai

Main Article Content

Abstract

Myasthenia gravis is a rare autoimmune disorder that can result in death. The genotypic role of the Human Leucocyte Antigen (HLA) system in myasthenia gravis is a growing topic of research interest in Vietnam. This study was conducted with 33 patients with myasthenia gravis at Can Tho General Hospital between September 2019 and December 2021. Analysis revealed 13 types of alleles in the HLA-DRB1 locus, with HLA-DRB1*12 (24.2%) being the most common. Patients with myasthenia gravis carrying the HLA-DRB1*13 genotype are at increased risk of elevated serum anti-acetylcholine receptor antibody levels (p = 0.031). There was a correlation between those with myasthenia gravis carrying the HLA-DRB1*10 genotype and moderate to severe disease severity. The results of this study emphasize the importance of proactive monitoring of the risk of disease progression in patients with these specific genotypes.

Article Details

Keywords

Genotype, HLA-DRB1, myasthenia gravis

References

1. Hehir MK, Silvestri NJ. Generalized Myasthenia Gravis: Classification, Clinical Presentation, Natural History, and Epidemiology. Neurologic clinics. 2018; 36(2): 253-260.
2. Hehir MK, Silvestri NJ. Generalized Myasthenia Gravis: Classification, Clinical Presentation, Natural History, and Epidemiology. Neurologic Clinics. 2018; 36(2): 253-260.
3. Zhong H, Zhao C, Luo S. HLA in myasthenia gravis: From superficial correlation to underlying mechanism. Autoimmun Rev. 2019; 18(9): 102349.
4. Nils Erik Gilhus ST. Myasthenia gravis. Disease Primer. 2019; 5:30.
5. Fan L, Ma S, Yang Y, Yan Z, Li J, Li Z. Clinical differences of early and late-onset myasthenia gravis in 985 patients. Neurological research. 2019; 41(1): 45-51.
6. Martinka I, Fulova M, Spalekova M, Spalek P. Epidemiology of Myasthenia Gravis in Slovakia in the Years 1977-2015. Neuroepidemiology. 2018; 50(3-4): 153-159.
7. Soltys J, Gong B, Kaminski HJ, Zhou Y, Kusner LL. Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment? Ann N Y Acad Sci. 2008; 1132:220-224.
8. T.H. Popperud MIB, M. Rasmussen, E. Kerty. Juvenile myasthenia gravis in Norway: Clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort. Official Journal of the European Paediatric Neurology Society. 2017; 21 707–714.
9. Nguyễn Thanh Bình NTT. Đặc điểm kiểu gen HLA các mẫu máu cuống rốn lưu trữ tại Bẹnh viện nhi Trung Ương. Tạp chí Nghiên cứu Y học. 2021; 143 (7) 8-14.
10. Xie Y-c, Qu Y, Sun L, et al. Association between HLA-DRB1 and myasthenia gravis in a northern Han Chinese population. Journal of Clinical Neuroscience. 2011; 18(11): 1524-1527.
11. Suzuki S, Kuwana M, Yasuoka H, Tanaka K, Fukuuchi Y, Kawakami Y. Heterogeneous immunogenetic background in Japanese adults with myasthenia gravis. Journal of the Neurological Sciences. 2001; 189(1): 59-64.
12. Vieira ML, Caillat-Zucman S, Gajdos P, Cohen-Kaminsky S, Casteur A, Bach J-F. Identification of genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis. Journal of Neuroimmunology. 1993; 47(2): 115-122.
13. Alahgholi-Hajibehzad M, Yilmaz V, Gulsen-Parman Y, et al. Association of HLA-DRB1 *14, -DRB1 *16 and -DQB1 *05 with MuSK-myasthenia gravis in patients from Turkey. Hum Immunol. 2013; 74(12): 1633-1635.
14. Feng X, Li W, Song J, et al. HLA typing using next-generation sequencing for Chinese juvenile- and adult-onset myasthenia gravis patients. J Clin Neurosci. 2019; 59: 179-184.